Show simple item record

dc.contributor.authorMonaghan, Phillip J
dc.contributor.authorOwen, L J
dc.contributor.authorTrainer, Peter J
dc.contributor.authorBrabant, Georg E
dc.contributor.authorKeevil, B G
dc.contributor.authorDarby, Denise
dc.date.accessioned2012-04-20T10:40:00Z
dc.date.available2012-04-20T10:40:00Z
dc.date.issued2011-09
dc.identifier.citationComparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone. 2011, 48 (Pt 5):441-6 Ann Clin Biochemen_GB
dc.identifier.issn1758-1001
dc.identifier.pmid21813575
dc.identifier.doi10.1258/acb.2011.011014
dc.identifier.urihttp://hdl.handle.net/10541/219593
dc.description.abstractThe accurate measurement of cortisol by immunoassay is compromised by the potential for cross-reactivity of reagent antibodies with structurally related steroids present in serum. This susceptibility is potentiated when normal steroid metabolism is altered pharmaceutically by antisteroidogenic drugs utilized in the management of Cushing's syndrome to moderate cortisol production. The clinical implications of falsely elevated cortisol results include over-treatment and unrecognized hypoadrenalism. To investigate the effect of the 11β-hydroxylase inhibitor metyrapone on serum cortisol assay, a comparison of measurement by immunoassay versus liquid chromatography-tandem mass spectrometry (LC-MS/MS) was conducted.
dc.language.isoenen
dc.rightsArchived with thanks to Annals of clinical biochemistryen_GB
dc.subject.meshChromatography, Liquid
dc.subject.meshCushing Syndrome
dc.subject.meshDiagnostic Techniques and Procedures
dc.subject.meshDrug Monitoring
dc.subject.meshFalse Positive Reactions
dc.subject.meshHumans
dc.subject.meshHydrocortisone
dc.subject.meshImmunoassay
dc.subject.meshMetyrapone
dc.subject.meshSteroid 11-beta-Hydroxylase
dc.subject.meshTandem Mass Spectrometry
dc.titleComparison of serum cortisol measurement by immunoassay and liquid chromatography-tandem mass spectrometry in patients receiving the 11β-hydroxylase inhibitor metyrapone.en
dc.typeArticleen
dc.contributor.departmentBiochemistry Department, The Christie NHS Foundation Trust, Withington, Manchester M20 4BX, UK. phillip.monaghan@nhs.neten_GB
dc.identifier.journalAnnals of Clinical Biochemistryen_GB
html.description.abstractThe accurate measurement of cortisol by immunoassay is compromised by the potential for cross-reactivity of reagent antibodies with structurally related steroids present in serum. This susceptibility is potentiated when normal steroid metabolism is altered pharmaceutically by antisteroidogenic drugs utilized in the management of Cushing's syndrome to moderate cortisol production. The clinical implications of falsely elevated cortisol results include over-treatment and unrecognized hypoadrenalism. To investigate the effect of the 11β-hydroxylase inhibitor metyrapone on serum cortisol assay, a comparison of measurement by immunoassay versus liquid chromatography-tandem mass spectrometry (LC-MS/MS) was conducted.


This item appears in the following Collection(s)

Show simple item record